Erschienen in:
26.07.2022 | ASO Author Reflections
ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma
verfasst von:
Mohamed A. Adam, MD, Alexa C. Glencer, MD, Amir H. Zureikat, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
Nonpancreatic periampullary (ampullary, duodenal, and extrahepatic cholangiocarcinoma) cancers are aggressive malignancies typically managed with surgical resection; however, survival remains poor. Neoadjuvant systemic therapy has become increasingly accepted for pancreatic ductal adenocarcinoma (PDAC).
1 However, the role of neoadjuvant chemotherapy for nonpancreatic periampullary adenocarcinomas has been poorly defined. Published data are limited to single-institution retrospective reviews with small cohorts. Adam et al.
2 examined the association of receipt of neoadjuvant chemotherapy with survival for patients with nonpancreatic periampullary adenocarcinomas. …